Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) – Equities researchers at Jefferies Financial Group issued their Q1 2019 EPS estimates for Amphastar Pharmaceuticals in a research note issued on Tuesday, March 12th. Jefferies Financial Group analyst D. Steinberg anticipates that the company will earn $0.06 per share for the quarter. Jefferies Financial Group also issued estimates for Amphastar Pharmaceuticals’ Q2 2019 earnings at $0.08 EPS, Q3 2019 earnings at $0.13 EPS and Q4 2019 earnings at $0.18 EPS.
A number of other research firms also recently commented on AMPH. BidaskClub upgraded Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, March 3rd. Zacks Investment Research upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 5th. Piper Jaffray Companies downgraded Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $24.00 to $23.00 in a report on Wednesday. Needham & Company LLC downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating and set a $22.20 price objective on the stock. in a report on Wednesday. Finally, TheStreet upgraded Amphastar Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Friday, January 11th. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Amphastar Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $23.73.
AMPH opened at $20.23 on Friday. Amphastar Pharmaceuticals has a one year low of $14.40 and a one year high of $25.43. The stock has a market capitalization of $1.11 billion, a PE ratio of 96.33, a price-to-earnings-growth ratio of 1.81 and a beta of 1.40. The company has a current ratio of 2.02, a quick ratio of 1.34 and a debt-to-equity ratio of 0.10.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Tuesday, March 12th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Amphastar Pharmaceuticals had a positive return on equity of 3.25% and a negative net margin of 1.96%. The business had revenue of $89.69 million for the quarter, compared to the consensus estimate of $75.46 million.
In related news, CFO William J. Peters sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $25.36, for a total transaction of $38,040.00. Following the transaction, the chief financial officer now owns 77,050 shares in the company, valued at approximately $1,953,988. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jason B. Shandell sold 7,500 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $24.99, for a total value of $187,425.00. Following the transaction, the insider now owns 175,818 shares in the company, valued at approximately $4,393,691.82. The disclosure for this sale can be found here. Insiders have sold a total of 87,222 shares of company stock worth $2,037,797 in the last 90 days. 31.50% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in AMPH. Wells Fargo & Company MN lifted its position in Amphastar Pharmaceuticals by 22.2% during the 3rd quarter. Wells Fargo & Company MN now owns 241,037 shares of the company’s stock worth $4,638,000 after acquiring an additional 43,727 shares during the period. Skandinaviska Enskilda Banken AB publ lifted its position in Amphastar Pharmaceuticals by 6.4% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 152,300 shares of the company’s stock worth $2,930,000 after acquiring an additional 9,200 shares during the period. Bessemer Group Inc. acquired a new stake in Amphastar Pharmaceuticals during the 3rd quarter worth approximately $620,000. Bank of New York Mellon Corp lifted its position in Amphastar Pharmaceuticals by 2.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 418,903 shares of the company’s stock worth $8,060,000 after acquiring an additional 10,837 shares during the period. Finally, Martingale Asset Management L P acquired a new stake in Amphastar Pharmaceuticals during the 3rd quarter worth approximately $2,033,000. Hedge funds and other institutional investors own 48.22% of the company’s stock.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Recommended Story: Percentage Decliners
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.